Recruited by Blackstone private equity fund to conduct business development, corporate planning, and fund reports as a portfolio company.Conduct midterm planning, sales force restructuring, and contract negotiation for generic and biosimilar drug sales/production license transfer and partnership.・Domestic and International license in/out contract and negotiation・Business acquisition ・Restructuring・Mid-term plan development・Marketing strategy plan/analysis・Board member steering committee management ・Reporting to PE Blackstone Portfolio management team

Co-founder of the Liquet Co., Ltd and running a career change support platform Career Suite. Acquired $200,000 Investment from DRG Venture Capital in a seed round.https://careersuite.jp/

We are developing and selling a headache treatment app with pattern recognition to improve behaviors and alleviate symptoms. Our goal is to obtain regulatory approval for our system. We would like to collaborate with businesses interested in exploring and validating our product for B2B purposes.

Healthcare Industry Advisory (HIA)•Pharmaceutical company: develop data governance strategy, operation and structure of a committee.•Pharmaceutical company: drew strategic marketing plan based on analytics for a rare disease drug and supported operational implementation.•Pharmaceutical company: plan and support to build a data governance scheme, structure and a committee from scratch.•Pharmaceutical company: conduct PMO to develop MR sales plan support AI system•Heavy industrial company: conduct PMO to introduce an indirect material procurement system for the entire group.•Insurance company: consult with IT and strategy sections to build a data warehouse for IT digital strategy plan.

•Analyze documentation data with mixed-method data analysis software for Harvard Business School Doctoral student: Yusaku Takeda's research

•Administrated parts of Dr. Richard Olson’s project: determining protein complexes relating to biofilm formation.•Proposed target genes or experiments by paper research and operated cell culture or protein purification process to proceed with our project.

•Joined Dr. Madhuri Wadehra’s project: determine the relationship between epithelial membrane protein-2 and cancer stem cell, PDL-1 expression, or EMP2 targeting antibody-dependent cell-mediated cytotoxicity.•Assessed cancer stem cells’ tolerance against our target gene for cancer therapy showing the significance of our research and publication is under review now.